---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-017067"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T05:17:28.877457+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago

## Summary
- Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.
- Q4 net income of $515k ($0.06 diluted EPS) vs net loss of $1.14M ($0.15) in Q4 2023.
- Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023; EBITDA turned positive at $1.33M.
- No contamination events since April 2024; management believes remediation is effective.
- Pending FDA clearance for Re-Tain®; NADA submitted Jan 2025 seeking expedited review.

## SEC filing metadata
- accession: 0001213900-25-017067
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/0001213900-25-017067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/ea0232079-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-017067
- JSON: https://secwatch.observer/filing/0001213900-25-017067.json
- Plain text: https://secwatch.observer/filing/0001213900-25-017067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.